Mice Model Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Mice Model Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The global Mice Model Market is expected to register a CAGR of 6.8% over the forecast period (2022-2027).

The Covid-19 pandemic has had a significant impact on the market studied. Mice models have been extensively used in the pre-clinical development by various research laboratories and biopharmaceutical industries. According to the article “Animal Models for COVID-19: Hamsters, Mouse, Ferret, Mink, Tree Shrew, and Non-human Primates” published in August 2021, various antiviral agents and vaccines have so far been evaluated in transgenic mouse models for COVID-19 and in the research mentioned above, the researchers adopted two main approaches for circumventing the incompatibility of mouse angiotensin-converting enzyme-2 (mACE2) with SARS-CoV-2 S protein such as the use of mouse-adapted SARS-CoV-2 strains; and expression of human ACE2 (hACE2) in mice. Thus, such adoption of mouse models to analyze the progress made since the discovery of SARS-CoV-2 in the development and application of relevant mouse models is anticipated to drive market growth during the pandemic. Therefore, the pandemic is expected to significantly impact the studied market growth.

Factors such as increasing innovations in mice models, rising demand for personalized medicine, and growing pipeline of pharmaceutical and biopharmaceutical companies are driving the growth of the mice model market.

Mice models are one of the best small animal models for various infectious diseases, including hepatitis B virus (HBV), hepatitis C virus (HCV), Zika virus, and cytomegalovirus (CMV), among others. Therefore, these mice models are widely used for several different viral investigations in pre-clinical research. The article “Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia” published in June 2022 stated that the genetic engineering of novel mouse models using knock-in approaches addresses some of the limitations of genetic mutations. Also, the article mentioned in its conclusion that the scientific community should use the open-access mouse model as a resource to study disease-relevant biology. Thus, such instances are anticipated to boost the demand for mice models, further driving the market growth.

In addition, mice have a few advantages over other model organisms, including a genome that is 99% similar to the human genome, a robust genetic/molecular toolkit, and the animal's tiny size, which makes it an economical model for large-scale, high-throughput research. In the article “How Necessary are Animal Models for Modern Drug Discovery?” published in September 2021 stated that due to improved human tissue engraftment and the ability of transplanted tissues to perform close to normal organ/tissue functions, research into several human diseases is progressing utilizing humanized mouse models. Thus, such advantages of the mouse models are expected to contribute to the market growth over the forecast period.

Thus, the mice model market is expanding, with the increase in research activities in the pharmaceutical industries. However, alternatives to animal testing and regulations for the ethical use of animals are expected to restrain the growth of the market.

Key Market TrendsThe Oncology Segment is Expected to Hold a Significant Market Share Over the Forecast Period

The oncology by application segment is expected to witness significant growth over the forecast period. The major factor propelling the segment's growth is the rising burden of cancer, coupled with the increasing adoption of mice models in various oncology-related drug and vaccine development research.

There is increasing use of mice models for drug discovery and therapeutics development in the field of oncology. And there are several advances in oncology that are expected to fuel market growth. For instance, in February 2021, ExpreS2ion Biotech Holding and the University of Bologna entered into a research collaboration agreement that covers testing of the novel HER2-cVLP breast cancer vaccine program, including the selected lead candidate ES2B-C001, in proprietary state-of-the-art breast cancer mice models.

In addition, the increasing research using mouse models for drug discovery for cancer is also anticipated to contribute to the market growth. For example, as per the article “A diversity outbred F1 mouse model identifies host-intrinsic genetic regulators of response to immune checkpoint inhibitors” published in April 2022, the researchers utilized the Diversity Outbred (DO) and Collaborative Cross (CC) mouse models, to investigate the outcomes of the immune checkpoint inhibitors (ICI) for a variety of malignancies. The researchers of the study purchased the DO mice models from the Jackson Laboratory and all CC mice from the Systems Genetics Core Facility at the University of North Carolina. Such adoption of mice models in cancer research is expected to contribute to segment growth.

Furthermore, the Institute of Cancer Research, London, stated that mice could be easily genetically altered to study the genetic causes of cancer and reproduce tumor types that naturally occur in humans. For instance, a study titled “Utilizing preclinical models to develop targeted therapies for rare central nervous system cancers” published in November 2021 stated that the researchers of the study used genetically engineered mouse models (GEMMs) created by introducing specific changes in the mouse genome by the Cre-Lox system, in utero electroporation, RCAS/tv-a system, or with Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 technology to develop targeted therapies for rare central nervous system cancers. Such instances show an increasing application of mouse models for oncology applications. This is further expected to drive market growth.

Therefore, the application of mouse models is expected to revolutionize drug discovery research, such as developing and verifying various cancer therapies, including cancer immunotherapy. Thereby, expected to boost the segment growth over the forecast period.

North America is Expected to Dominate the Market Over the Forecast Period

North America is anticipated to witness growth over the forecast period and dominate the market. Among other countries in the region, the United States is leading the market, due to factors such as an increase in healthcare expenditure, increasing research and developments, and a rising prevalence of various communicable or non-communicable diseases. Additionally, the rising geriatric population across the United States is the primary driver for the United States mice model market.​

The market players in the country are involved in various activities such as collaborations and agreements which are anticipated to drive the market growth over the forecast period. For instance, in May 2021, the SDS Alliance launched a Mouse Model Project with the Jackson Laboratory. The project will create the mouse model (introduce SDS disease genes into mice using CRISPR and breed) for USD 150,000 and characterize the model (such as how does SDS present in mice compared to human SDS or do the mice get pancreatic problems or neutropenia) for another USD 150,000.

In addition, in November 2021, Tranquis Therapeutics, a private immuno-neurology company declared positive preclinical data on its lead program TQS-168 at the Neuroscience 2021 meeting. The data illustrate the potential of TQS-168 for the treatment of amyotrophic lateral sclerosis (ALS). TQS-168 showed increased median survival and decreased pro-inflammatory cytokines and inflammatory monocytes in a widely used SOD1-G93A transgenic mouse model and demonstrated a similar decrease in inflammatory monocytes in blood from ALS patients. Such advances in the country are anticipated to fuel market growth.

Therefore, owing to the factors mentioned above, North America is predicted to witness growth over the forecast period.

Competitive Landscape

The Mice Model Market is made up of a network of players involved in research and product development, component manufacturing, distribution and sales, and post-sale services. The leading players in the market are offering services and CRISPR technologies as service models, which is experiencing an uptrend due to increased drug development activity. Some of the market players are Allentown LLC, Charles River Laboratories International Inc., ENVIGO, Genoway, Harbour Biomed, and The Jackson Laboratory, among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.